{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:49:04Z","timestamp":1792417744001,"version":"4.4.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J Fox Foundation for Parkinson&apos;s Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.parkreldis.2022.10.019","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T03:58:14Z","timestamp":1666929494000},"page":"90-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Renin-angiotensin system blockers affect cognitive decline in Parkinson's disease: The PPMI dataset"],"prefix":"10.1016","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6266-9701","authenticated-orcid":false,"given":"Jianhua","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingrui","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuijing","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2022.10.019_bib1","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/WNL.0b013e3181f39d0e","article-title":"Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis","volume":"75","author":"Aarsland","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2022.10.019_bib2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/archneur.60.3.387","article-title":"Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study","volume":"60","author":"Aarsland","year":"2003","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.parkreldis.2022.10.019_bib3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.parkreldis.2021.03.007","article-title":"Effects of angiotensin type 1 receptor antagonists on Parkinson's disease progression: an exploratory study in the PPMI database","volume":"86","author":"Udovin","year":"2021","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2022.10.019_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fnsyn.2021.638519","article-title":"The renin-angiotensin system modulates dopaminergic neurotransmission: a new player on the scene","volume":"13","author":"Kobiec","year":"2021","journal-title":"Front. Synaptic Neurosci."},{"key":"10.1016\/j.parkreldis.2022.10.019_bib5","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/13543784.2017.1371133","article-title":"Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson's disease","volume":"26","author":"Perez-Lloret","year":"2017","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.parkreldis.2022.10.019_bib6","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.neuropharm.2013.05.025","article-title":"Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of \u03b1-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL\/6J mice","volume":"73","author":"Sathiya","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.parkreldis.2022.10.019_bib7","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/joim.12838","article-title":"Connecting the brain cholesterol and renin-angiotensin systems: potential role of statins and RAS-modifying medications in dementia","volume":"284","author":"Petek","year":"2018","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.parkreldis.2022.10.019_bib8","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3389\/fphar.2018.00440","article-title":"Targeting renin-angiotensin system Against Alzheimer's disease","volume":"9","author":"Gebre","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"2020","key":"10.1016\/j.parkreldis.2022.10.019_bib9","first-page":"1464","article-title":"AT2R's (angiotensin II type 2 Receptor's) role in cognitive and cerebrovascular deficits in a mouse model of Alzheimer disease","volume":"75","author":"Royea","year":"1979","journal-title":"Hypertension (Dallas, Tex."},{"key":"10.1016\/j.parkreldis.2022.10.019_bib10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.pneurobio.2011.09.005","volume":"95","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.parkreldis.2022.10.019_bib11","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/acn3.644","article-title":"The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort","volume":"5","author":"Marek","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.parkreldis.2022.10.019_bib12","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.bcp.2018.01.047","article-title":"Angiotensin 1-7 ameliorates 6-hydroxydopamine lesions in hemiparkinsonian rats through activation of MAS receptor\/PI3K\/Akt\/BDNF pathway and inhibition of angiotensin II type-1 receptor\/NF-\u03baB axis","volume":"151","author":"Rabie","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.parkreldis.2022.10.019_bib13","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1474-4422(21)00263-5","article-title":"Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"20","author":"Kehoe","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2022.10.019_bib14","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1176\/appi.ajp.2014.13111543","article-title":"Association of gene variants of the renin-angiotensin system with accelerated hippocampal volume loss and cognitive decline in old age","volume":"171","author":"Zannas","year":"2014","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.parkreldis.2022.10.019_bib15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00401-019-02098-6","article-title":"ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer's disease","volume":"139","author":"Evans","year":"2020","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.parkreldis.2022.10.019_bib16","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00401-013-1121-x","article-title":"Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease","volume":"126","author":"Zhang","year":"2013","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.parkreldis.2022.10.019_bib17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0000000000001098","article-title":"CSF biomarkers and clinical progression of Parkinson disease","volume":"84","author":"Hall","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2022.10.019_bib18","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.ajpath.2013.12.007","article-title":"Cerebrospinal fluid \u03b1-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort","volume":"184","author":"Stewart","year":"2014","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.parkreldis.2022.10.019_bib19","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1212\/WNL.0000000000004705","article-title":"SNPs in A\u03b2 clearance proteins: lower CSF A\u03b2(1-42) levels and earlier onset of dementia in PD","volume":"89","author":"Brockmann","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2022.10.019_bib20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/bs.irn.2016.12.001","article-title":"Cerebrospinal fluid biomarkers of cognitive decline in Parkinson's disease","volume":"132","author":"Johar","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.parkreldis.2022.10.019_bib21","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","article-title":"Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline","volume":"30","author":"Clinton","year":"2010","journal-title":"J. Neurosci. : the official journal of the Society for Neuroscience"},{"key":"10.1016\/j.parkreldis.2022.10.019_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2022.109120","article-title":"\u03b1-synuclein-assisted oligomerization of \u03b2-amyloid (1-42)","volume":"717","author":"Chau","year":"2022","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.parkreldis.2022.10.019_bib23","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S1474-4422(20)30314-8","article-title":"Amyloid-PET and (18)F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias","volume":"19","author":"Ch\u00e9telat","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2022.10.019_bib24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1600-0404.2005.00411.x","article-title":"Can Alzheimer's type pathology influence the clinical phenotype of Parkinson's disease?","volume":"111","author":"Papapetropoulos","year":"2005","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.parkreldis.2022.10.019_bib25","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3233\/JAD-180390","article-title":"Brain amyloid contribution to cognitive dysfunction in early-stage Parkinson's disease: the PPMI dataset","volume":"66","author":"Fiorenzato","year":"2018","journal-title":"J. Alzheim. Dis. : JAD"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802022003479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802022003479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:26:39Z","timestamp":1761179199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802022003479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":25,"alternative-id":["S1353802022003479"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2022.10.019","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renin-angiotensin system blockers affect cognitive decline in Parkinson's disease: The PPMI dataset","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2022.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}